

Nurosene to Present at the H.C. Wainwright Bioconnect Virtual Investor Conference on January 10-13, 2022

TORONTO, Jan. 6, 2022 /CNW/ - Nurosene Health Inc. ("Nurosene" or the "Company") (CSE: MEND) (Frankfurt: 8TV) (OTC: MNNDF), a healthtech company focused on building a generation of better brains, today announced that George Achilleos, President and Chief Operating Officer, will participate in the H.C. Wainwright Bioconnect Virtual Conference taking place January 10th through the 13th, 2022.

Mr. Achilleos's investor presentation will be available on-demand beginning January 10th at 7 a.m. ET.

Management will be available during the H.C. Wainwright Bioconnect Conference for 1x1 meetings with the investment community. To schedule a meeting please reach out to your HCW representative or KCSA Strategic Communication by emailing Nurosene@kcsa.com.

For further information about the H.C. Wainwright Bioconnect Conference and to register to attend virtually [click here](#).

About Nurosene

Nurosene provides individuals with tools and technology that empower them to take control of their mental wellness. Our mission is to build the next generation of better, healthier brains by leveraging technological advancements in AI. With our team of experts and partners, Nurosene is positioned at the leading edge of critical research and innovations, striving to disrupt traditional mental wellness treatments.

For more information, visit www.nurosene.com.

Forward-Looking Statements


This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which is based upon Nurosene's current internal expectations, estimates, projections, assumptions and beliefs, and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information includes estimates, plans, expectations, opinions, forecasts, projections, targets, guidance, or other statements that are not statements of fact.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, Nurosene does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors

emerge from time to time, and it is not possible for Nurosene to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in Nurosene's Final Long Form Prospectus dated May 20, 2021 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in Nurosene's Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.

The CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Nurosene Health Inc.

 View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/January2022/06/c0798.html>

%SEDAR: 00050449E

For further information: Blake Sing, Chief Financial Officer, investors@nurosene.com, (416) 859-8838; KCSA Strategic Communications: Valter Pinto, Managing Director, Valter@KCSA.com, (212) 896-1254

CO: Nurosene Health Inc.

CNW 10:29e 06-JAN-22